TY - JOUR
T1 - A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants
AU - Navazesh, Mahvash
AU - Mulligan, Roseann
AU - Barrón, Yolanda
AU - Redford, Maryann
AU - Greenspan, Deborah
AU - Alves, Mario
AU - Phelan, Joan
N1 - Funding Information:
The Oral Substudy of the Women's Interagency HIV Study (WIHS) Collaborative Study Group includes the following groups: New York City/Bronx Consortium, New York University (Joan Phelan, DDS); The Connie Wofsy Study Consortium of Northern California, University of California, San Francisco (Deborah Greenspan, BDS, DSc, John S. Greenspan, BDS, PhD, FRC Path, Laurie A. Macphail, D.D.S.); Los Angeles County/Southern California Consortium, University of Southern California, Los Angeles (Roseann Mulligan, DDS, MS, Mahvash Navazesh, DMD, Joyce Galligan, RN, DDS, Lupe Arevalo, RDH, Sharon Bautista-King, Claudia Vargas); Chicago Consortium, University of Illinois at Chicago (Mario Alves, DDS, MS, DSc); Data Coordinating Center, John Hopkins University Bloomberg School of Public Health, Baltimore, Md (Stephen J. Gange, PhD, Yolanda Barron, MS); National Institutes of Health, The National Institute of Dental and Craniofacial Research (Maryann Redford, DDS, MPH). The WIHS is funded by the National Institute of Allergy and Infectious Diseases, with supplemental funding from the National Cancer Institute, the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Dental and Craniofacial Research, the Agency for Health Care and Policy and Research, and the Centers for Disease Control and Prevention: U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-HD-32632, U01-AI-34993, U01-AI-42590.
PY - 2003/6
Y1 - 2003/6
N2 - Objectives. Our purpose was to conduct a longitudinal investigation of xerostomia and salivary gland hypofunction in a national cohort of HIV-positive and at-risk HIV-negative participants in the Women's Interagency HIV Study. Study design. Data included responses to a dry mouth questionnaire, clinical evaluations of major salivary glands, and unstimulated and chewing-stimulated whole salivary flow rates. Repeated measures regression models were used to determine factors associated with xerostomia and salivary gland hypofunction. Results. Significant univariate associations were found between HIV status and reports of "too little saliva" (P < .0001), ≤0.1 mL/min, unstimulated saliva (P = .01), and lack of saliva upon palpation of parotid (P = .02) and submandibular/sublingual salivary glands (P = .03). Adjusted odds of reports of "too little saliva" were significantly higher for HIV-positive participants (odds ratio [OR] = 2.44; 95% CI, 1.49 - 3.97; P = .0004) than for HIV-negative participants. Among HIV-positive women, adjusted odds of reports of "too little saliva" and of ≤0.7 mL/min chewing-stimulated saliva were significantly higher for those with CD4 < 200 (OR = 1.58; 95% CI, 1.07-2.34; P = .022; and OR = 1.53; 95% CI, 1.05-2.23; P = .027, respectively) and for those with CD4 200-500 (OR = 1.47; 95%CI, 1.07-2.02; P = 0.016; and OR = 1.37; 95% CI, 1.01-2.31; P = .001, respectively) than for those with CD4 > 500. Also, adjusted odds of ≤0.1 mL/min unstimulated saliva and ≤0.7 mL/min chewing-stimulated saliva were significantly higher in women on highly active antiretroviral therapy (HAART) (OR = 1.25; 95% CI, 1.05 - 1.50; P = .014) than in women not on HAART (OR = 1.34; 95% CI, 1.01 - 1.79; P = .044). Conclusions. HIV-positive women are at a significantly higher risk for xerostomia and salivary gland hypofunction than HIV-negative women, and low CD4 cell counts and HAART use are significant risk factors for these conditions.
AB - Objectives. Our purpose was to conduct a longitudinal investigation of xerostomia and salivary gland hypofunction in a national cohort of HIV-positive and at-risk HIV-negative participants in the Women's Interagency HIV Study. Study design. Data included responses to a dry mouth questionnaire, clinical evaluations of major salivary glands, and unstimulated and chewing-stimulated whole salivary flow rates. Repeated measures regression models were used to determine factors associated with xerostomia and salivary gland hypofunction. Results. Significant univariate associations were found between HIV status and reports of "too little saliva" (P < .0001), ≤0.1 mL/min, unstimulated saliva (P = .01), and lack of saliva upon palpation of parotid (P = .02) and submandibular/sublingual salivary glands (P = .03). Adjusted odds of reports of "too little saliva" were significantly higher for HIV-positive participants (odds ratio [OR] = 2.44; 95% CI, 1.49 - 3.97; P = .0004) than for HIV-negative participants. Among HIV-positive women, adjusted odds of reports of "too little saliva" and of ≤0.7 mL/min chewing-stimulated saliva were significantly higher for those with CD4 < 200 (OR = 1.58; 95% CI, 1.07-2.34; P = .022; and OR = 1.53; 95% CI, 1.05-2.23; P = .027, respectively) and for those with CD4 200-500 (OR = 1.47; 95%CI, 1.07-2.02; P = 0.016; and OR = 1.37; 95% CI, 1.01-2.31; P = .001, respectively) than for those with CD4 > 500. Also, adjusted odds of ≤0.1 mL/min unstimulated saliva and ≤0.7 mL/min chewing-stimulated saliva were significantly higher in women on highly active antiretroviral therapy (HAART) (OR = 1.25; 95% CI, 1.05 - 1.50; P = .014) than in women not on HAART (OR = 1.34; 95% CI, 1.01 - 1.79; P = .044). Conclusions. HIV-positive women are at a significantly higher risk for xerostomia and salivary gland hypofunction than HIV-negative women, and low CD4 cell counts and HAART use are significant risk factors for these conditions.
UR - http://www.scopus.com/inward/record.url?scp=0037660721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037660721&partnerID=8YFLogxK
U2 - 10.1067/moe.2003.230
DO - 10.1067/moe.2003.230
M3 - Article
C2 - 12789150
AN - SCOPUS:0037660721
SN - 1079-2104
VL - 95
SP - 693
EP - 698
JO - Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
JF - Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
IS - 6
ER -